GVR Report cover Postmenopausal Osteoporosis Treatment Market Size, Share and Trend Report

Postmenopausal Osteoporosis Treatment Market Size, Share and Trend Analysis Report By Drug Type (Vitamin D3 Derivative, Hormone Replacement Therapy, Parathyroid Hormone Therapy), By Distribution Channel, By Region, and Segment Forecasts, 2023 to 2030

  • Report ID: GVR453960
  • Number of Pages: 0
  • Format: Electronic (PDF)

Menopause is the most common cause of osteoporosis, and the world is witnessing rise in burden of disease in postmenopausal women which is the key factor driving the market. According to an article published in March 2021, around 33.1% of postmenopausal women were affected with the disease and it is estimated to increase in prevalence to 50% in coming years. International Menopause Society (IMS) estimates 1 in 3 women above 50 years old report fractures due to osteoporosis. Moreover, rising geriatric population and lifestyle changes such has sedentary lifestyle, high alcohol consumption, unhealthy eating habits are impacting menstruating period of female and increasing risk of disease.

Government and private organizations are actively taking initiatives to raise the awareness about the condition in society and fueling the market growth. Every year October 18 and October 20 are dedicated as World Menopause Day and World Osteoporosis Day, respectively to highlight the challenges of postmenopausal osteoporosis symptoms and related treatment for management of disease. Moreover, in January 2021, pan-Asia Pacific clinical practice standards were launched by Asia Pacific Consortium on Osteoporosis (APCO) to screen, diagnose, and management of disease. All these aforementioned factors are increasing the awareness and driving the postmenopausal osteoporosis treatment market.

Postmenopausal osteoporosis treatment market is segmented by drug type as:

  • Bisphosphonates

  • Vitamin D3 derivatives

  • Estrogen agonist/antagonist

  • Hormone replacement therapy

  • Parathyroid hormone therapy

  • Others

The space has presence of medications such as bisphosphonates, vitamin D3 derivatives, selective estrogen receptor modulator (SERM), hormone replacement therapy and parathyroid hormone therapy that help to promote bone growth & stability and prevent bone from breaking down.

According to the new guidelines, patients at a very high risk of fracture should be prescribed denosumab, abaloparatide, teriparatide, romosozumab, and zoledronate as initial therapy. Postmenopausal patients diagnosed with osteoporosis, but not at very high risk of fracture, should be considered high-risk patients and be prescribed denosumab, alendronate, risedronate, and zoledronate. The inclusion of newly approved products, such as Evenity, in the revised treatment guidelines is likely to boost market growth. There are several drugs under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative opportunities for market growth. For instance, Gedeon Richter Plc’s drug candidate RGB-14-P is under phase 3 clinical trial for postmenopausal women with osteoporosis.

Major players are employing strategies such as new product launches, expansion, mergers & acquisitions, licensing partnerships, and co-development deals which fueling the market growth. For instance, in July 2022, Japanese firm Chugai Pharmaceutical Co., Ltd. launched vitamin D3 derivative drug Edirol (eldecalcitol) for postmenopausal women with disease in China.

                    Postmenopausal Osteoporosis Treatment Market Segmentation

Segments

Details

Drugs Type

Bisphosphonates, Vitamin D3 Derivative, Estrogen agonist/antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Others

Distribution Channel

Hospital pharmacies, Retail pharmacies, Others

Region

North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA)

 

Major companies operating in the market include Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Merck & Co., Novartis AG, Eli Lilly and Company., AbbVie (Allergan plc.), Cipla Inc, Amgen Inc., and F. Hoffmann-La Roche Ltd amongst others

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon